Korean Medication Algorithm Project for Bipolar Disorder 2018 (KMAP-BP 2018): Fourth Revision.
10.9758/cpn.2018.16.4.434
- Author:
Young Sup WOO
1
;
Won Myong BAHK
;
Jung Goo LEE
;
Jong Hyun JEONG
;
Moon Doo KIM
;
InKi SOHN
;
Se Hoon SHIM
;
Duk In JON
;
Jeong Seok SEO
;
Kyung Joon MIN
;
Won KIM
;
Hoo Rim SONG
;
Bo Hyun YOON
Author Information
1. Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, Korea. wmbahk@catholic.ac.kr
- Publication Type:Practice Guideline ; Original Article
- Keywords:
Bipolar disorder;
Expert consensus;
Drug therapy;
Practice guideline
- MeSH:
Adolescent;
Adolescent Psychiatry;
Adult;
Advisory Committees;
Bipolar Disorder*;
Child;
Consensus;
Depression;
Drug Therapy;
Humans;
Psychiatry
- From:Clinical Psychopharmacology and Neuroscience
2018;16(4):434-448
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: The Korean Medication Algorithm Project for Bipolar Disorder (KMAP-BP) was first published in 2002 through an expert consensus of opinion, and updated in 2006, 2010, and 2014. This study constitutes the fourth revision of the KMAP-BP. METHODS: A 50-item questionnaire was used to obtain the consensus of experts regarding pharmacological treatment strategies for various phases of adult bipolar disorder and six items for pediatric bipolar disorder. The review committee included 84 Korean psychiatrists and 43 child and adolescent psychiatry experts. RESULTS: The preferred first-step strategies for acute mania were the combination of a mood stabilizer (MS) and an atypical antipsychotic (AAP), MS monotherapy, and AAP monotherapy. A combination of a MS and an AAP, and AAP monotherapy were preferred for psychotic mania. The first-step strategies for mild to moderate bipolar depression were monotherapy with MS, AAP, or lamotrigine (LMT), and the combination of a MS and an AAP or LMT, or a combination of an AAP and LMT. The combination of two among a MS, AAP, and LMT were preferred for non-psychotic severe depression. A combination of a MS and an AAP or the combination of an AAP with an antidepressant or LMT were the first-line options for psychotic severe depression. CONCLUSION: The recommendations of the KMAP-BP 2018 have changed from the previous version by reflecting recent developments in pharmacotherapy for bipolar disorder. KMAP-BP 2018 provides clinicians with a wealth of information regarding appropriate strategies for treating patients with bipolar disorder.
